Skip to content
10-Q

Quarterly Report

Aclaris Therapeutics, Inc. ACRS

0001104659-26-057202

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 139.66M sh
Shares Diluted Q1 2026 · Mar 31, 2026 128.81M sh
Shares Diluted Q1 2026 · Mar 31, 2025 122.39M sh
Capex Q1 2026 · Mar 31, 2026 $13K
Capex Q1 2026 · Mar 31, 2025 $43K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$18.15M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.06M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $28.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $19.96M
Stockholders Equity Q1 2026 · Mar 31, 2026 $143.65M
Stockholders Equity Q1 2026 · Dec 31, 2025 $103.08M
Stockholders Equity Q1 2026 · Mar 31, 2025 $144.07M
Stockholders Equity Q1 2026 · Dec 31, 2024 $155.55M
Current Liabilities Q1 2026 · Mar 31, 2026 $27.37M
Current Liabilities Q1 2026 · Dec 31, 2025 $28.65M
Total Liabilities Q1 2026 · Mar 31, 2026 $55.07M
Total Liabilities Q1 2026 · Dec 31, 2025 $57.38M
Current Assets Q1 2026 · Mar 31, 2026 $110.23M
Current Assets Q1 2026 · Dec 31, 2025 $96.32M
Total Assets Q1 2026 · Mar 31, 2026 $198.72M
Total Assets Q1 2026 · Dec 31, 2025 $160.46M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.15
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.12
Eps Basic Q1 2026 · Mar 31, 2026 −$0.15
Eps Basic Q1 2026 · Mar 31, 2025 −$0.12
Sga Expense Q1 2026 · Mar 31, 2026 $6.74M
Sga Expense Q1 2026 · Mar 31, 2025 $6.14M
Rd Expense Q1 2026 · Mar 31, 2026 $15.66M
Rd Expense Q1 2026 · Mar 31, 2025 $11.58M
Net Income Q1 2026 · Mar 31, 2026 −$19.82M
Net Income Q1 2026 · Mar 31, 2025 −$15.09M
Operating Income Q1 2026 · Mar 31, 2026 −$22.19M
Operating Income Q1 2026 · Mar 31, 2025 −$18.08M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $395K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $506K
Revenue Q1 2026 · Mar 31, 2026 $2M
Revenue Q1 2026 · Mar 31, 2025 $1.46M